Specialty Pharmacy

Biohaven Achieves Positive Results in Pivotal Trial of Oral Nurtec for the Preventive Treatment of Migraine

NEW HAVEN, Conn., March 30, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results in its randomized, placebo-controlled pivotal clinical trial (NCT03732638) evaluating the efficacy and safety of oral rimegepant 75 mg for the preventive treatment of migraine in both episodic and chronic migraine …

Read More »

Engage Therapeutics Announces Phase 2b Study of Staccato Alprazolam for Seizure Cessation Meets Primary Endpoint

SUMMIT, N.J., March 12, 2020 (GLOBE NEWSWIRE) — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing an orally inhaled therapy designed to terminate an active epileptic seizure, today announced that its Phase 2b StATES study of Staccato® alprazolam met its primary endpoint which was proportion of responders achieving cessation of seizure …

Read More »

CVS Pharmacy to Acquire Schnuck Markets Retail and Specialty Pharmacy Businesses

WOONSOCKET, R.I., March 10, 2020 /PRNewswire/ — CVS Pharmacy, Inc., a subsidiary of CVS Health Corporation (NYSE: CVS), and Schnucks announced today that they have entered into a definitive agreement for CVS Pharmacy and certain of its subsidiaries to acquire Schnuck Markets Inc.’s retail and specialty pharmacy businesses. Through this …

Read More »

FDA Approves Allergan’s Durysta, a Long-Term Eye Implant for Patients with Glaucoma or Ocular Hypertension

DUBLIN, March 5, 2020 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s New Drug Application (NDA) for DURYSTA™ (bimatoprost implant) 10 mcg for …

Read More »

KabaFusion Acquires Lincare’s Infusion Pharmacies, Expanding Patient-Focused Home Infusion Services Nationwide

CERRITOS, Calif.–(BUSINESS WIRE)–KabaFusion, a leading provider of specialty acute and chronic home infusion therapies, today announced it has acquired the home infusion assets of Lincare, a subsidiary of Linde plc. The strategic combination strengthens KabaFusion’s position as the premier clinician-led home infusion company in the United States, significantly enhancing the …

Read More »

Biohaven’s Nurtec Receives FDA Approval for the Acute Treatment of Migraine in Adults

NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults. NURTEC ODT is the first FDA-approved product for Biohaven, a company dedicated …

Read More »

Acacia Pharma Announces FDA Approval of Barhemsys for Treatment and Prevention of Postoperative Nausea and Vomiting

Cambridge, UK and Indianapolis, US – 27 February 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer …

Read More »

Takeda to Acquire PvP Biologics and its Investigational Celiac Disease Drug in Deal Worth $330 Million

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced that it has acquired PvP Biologics, Inc. following the conclusion of a Phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062) for the treatment of uncontrolled celiac disease. TAK-062 is a potential best-in-class, highly potent super glutenase – a protein that …

Read More »

NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study of Aldafermin in NASH Patients

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on developing transformative therapeutics for patients, today announced positive preliminary topline results from the 24-week double-blind, randomized, placebo-controlled cohort (Cohort 4) of an adaptive Phase 2 study evaluating the efficacy, safety …

Read More »

FDA Approves Lundbeck’s Vyepti, the First and Only Intravenous Preventive Treatment for Migraine

DEERFIELD, Ill.–(BUSINESS WIRE)–Lundbeck today announced that VYEPTI™ (eptinezumab-jjmr) has been approved by the U.S. Food and Drug Administration (FDA) for the preventive treatment of migraine in adults and will be available in April 2020. The recommended dose is 100 mg every 3 months; some patients may benefit from a dose …

Read More »